ⅡB—ⅢB期宫颈鳞癌同步放化疗与新辅助化疗后同步放化疗疗效比较

doi:10.3760/cma.j.issn.1004-4221.2018.01.012

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract

Objective To investigate the long-term efficacy and prognosis of concurrent chemoradiotherapy alone and concurrent chemoradiotherapy after neoadjuvant chemotherapy for stage ⅡB-ⅢB cervical squamous cell carcinoma. Methods A retrospective analysis was performed among 171 patients with stage ⅡB-ⅢB cervical squamous cell carcinoma who were admitted to our hospital and had complete follow-up data from February 1,2005 to October 31,2011. Results The median follow-up time was 66 months. There were no significant differences in the 3-or 5-year overall survival rates between the concurrent group and the neoadjuvant group (81.4% vs. 75.9%,74.3% vs. 67.2%,P=0.469).According to the subgroup analysis,there was no correlation between lymph node metastasis and survival curve (P=0.310,P=0.151).The univariate and Cox multivariate analyses showed that tumor size,lymph node metastasis,and concurrent chemotherapy method were independent prognostic factors for cervical cancer (P<0.05).For the patients with lymph node metastasis,the neoadjuvant group had a significantly higher pelvic local recurrence rate than the concurrent group (P=0.047),while there were no significant differences in mortality,distant metastasis,or long-term adverse reactions between the two groups (all P>0.05).For the patients without lymph node metastasis,the neoadjuvant group had a significantly higher incidence of grade 3-4 bone marrow suppression than the concurrent group (P=0.016),while there were no significant differences in mortality,local recurrence,distant metastasis,or long-term adverse reactions between the two groups (all P>0.05). Conclusions Concurrent chemoradiotherapy alone and concurrent chemoradiotherapy after neoadjuvant chemotherapy achieve similar treatment outcomes in patients with stage ⅡB-ⅢB cervical squamous cell carcinoma,no matter whether they have lymph node metastasis or not. Tumor size,lymph node metastasis,and concurrent chemotherapy method are independent prognostic factors. Neoadjuvant chemotherapy increases the risk of grade 3-4 marrow suppression during concurrent chemoradiotherapy,prolongs irradiation time,and increases the risk of local recurrence.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Zheng Jie
	Wu Xingrao
	Ye Lan
	Wu Pengfei
	Ai Yiqin

Key words： Cervical neoplasms/concurrent chemoradiotherapy Cernical neoplasms/neoadjuvant chemotheraPy Prognosis

Received: 14 April 2017

Fund:

Health Science and Technology Plan of Yunnan Province (2014NS011,2016NS088)

Corresponding Authors: Ai Yiqin,Email aiyiqin@126.com

Cite this article:

Zheng Jie,Wu Xingrao,Ye Lan et al. A comparative analysis of the efficacy and prognosis of concurrent chemoradiotherapy alone and concurrent chemoradiotherapy after neoadjuvant chemotherapy for stage ⅡB-ⅢB cervical squamous cell carcinoma[J]. Chinese Journal of Radiation Oncology, 2018, 27(1): 58-62.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2018.01.012 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2018/V27/I1/58

[1] Green JA,Kirwan JM,Tierney JF,et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix:a systematic review and meta-analysis[J].Lancet,2001,358(9284):781-786.DOI:10.1016/S0140-6736(01)05965-7
[2] Narayan S,Sharma N,Kapoor A,et al. Pros and cons of adding of neoadjuvant chemotherapy to standard concurrent chemoradiotherapy in cervical cancer:a regional cancer center experience[J].J Obstet Gynecol India,2016,66(5):385-390.DOI:10.1007/s13224-015-0698-5
[3] Harsh KK,Kapoor A,Paramanandhan M,et al. Induction chemotherapy followed by concurrent chemoradiation in the management of different stages of cervical carcinoma:5-year retrospective study[J].J Obstet Gynecol India,2016,66(5):372-378.DOI:10.1007/s13224-015-0699-4
[4] 成荣杰,付艳.新辅助化疗在宫颈癌治疗中的研究现状[J].实用医学杂志,2010,26(3):352-354.DOI:10.3969/j.issn.1006-5725.2010.03.003.Cheng RJ,Fu Y.Research status of neoadjuvant chemotherapy in the treatment of uterine cervical cancer[J].J Pract Med,2010,26(3):352-354.DOI:10.3969/j.issn.1006-5725.2010.03.003
[5] 孙建衡.妇科恶性肿瘤放射治疗学[M].北京:中国协和医科大学出版社,2002:142.Sun JH. Radiotherapy for gynecologic malignancies[M].Beijing:China Unin Medical University Press,2002:142
[6] Tattersall MH,Lorvidhaya V,Vootiprux V,et al. Randomized trial of epirubicin and cisplatin chemotherapy followed by Pelvic radiation in locally advanced cervical cancer. Cervical cancer study group of the Asian Oceanian Clinical Oncology Association[J].J Clin Oncol,1995,13(2):444-451.DOI:10.1200/JCO.1995.13.2.444
[7] Kumar L,Grover R,Pokharel YH,et al. Neoadjuvant chemotherapy in locally advanced cervical cancer:two randomised studies[J].Aust N Z J Med,1998,28(3):387-390.DOI:10.1111/j.1445-5994.1998.tb01970.x
[8] Sundfør K,Tropé CG,Högberg T,et al. Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A[J].Cancer,1996,77(11):2371-2378.DOI:10.1002/(SICI)1097-0142(19960601)77:11<2371::AID-CNCR28>3.0.CO;2-T
[9] Symonds RP,Habeshaw T,Reed NS,et al. The Scottish and Manchester randomised trial of neo-adjuvant chemotheraPy for advanced cervical cancer[J].Eur J Cancer,2000,36(8):994-1001.DOI:10.1016/S0959-8049(00)00034-4
[10] 殷蔚伯,余子豪,徐国镇,等.肿瘤放射治疗学[M].4版.北京:人民卫生出版社,2008:1041-1043.Yin WB,Yu ZH,Xu ZG,et al. Radiation oncology[M].4th ed. Beijing:People′s Health Publishing House,2008:1041-1043
[11] 连利娟.林巧稚妇科肿瘤学[M].4版.北京:人民卫生出版社,2006:347.Lian LJ.Lin Qiaozhi gynecologic oncology[M].4th ed. Beijing:People′s Health Publishing House,2006:347
[12] 杜俊瑶,张新,李联昆.Ⅱb~Ⅲ期宫颈癌264例疗效及预后因素分析[J].中国实用妇科与产科杂志,2015,31(2):137-141.Du JY,Zhang X,Li LK.Outcomes and prognostic factors of cervical cancer in 264 patients of stage Ⅱ b-Ⅲ[J].Chin J Pract Gynecol Obstet,2015,31(2):137-141
[13] Reig A,Membrive I,Foro P,et al. Long-term results and Prognostic factors of Patients with cervical carcinoma treated with concurrent chemoradiotherapy[J].Clin Transl Oncol,2011,13(7):504-508.DOI:10.1007/s12094-011-0688-8
[14] Okazawa M,Mabuchi S,Isohashi F,et al. Impact of the addition of concurrent chemotherapy to Pelvic radiotherapy in surgically treated stage ⅠB1-ⅡB cervical cancer Patients with intermediate-risk or high-risk factors:a 13-year exPerience[J].Int J Gynecol Cancer,2013,23(3):567-575.DOI:10.1097/IGC.0b013e31828703fd
[15] Kong TW,Chang SJ,Paek J,et al. Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage ⅡB-IVA cervical cancer[J].J Gynecol Oncol,2012,23(4):235-241.DOI:10.3802/jgo.2012.23.4.235
[16] Einstein MH,Rash JK,Chappell RJ,et al. Quality of life in cervical cancer survivors:patient and provider perspectives on common complications of cervical cancer and treatment[J].Gynecol Oncol,2012,125(1):163-167.DOI:10.1016/j.ygyno.2011.10.033
[17] Nakano T,Kato S,Ohno T,et al. Long-term results of high-dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix[J].Cancer,2005,103(1):92-101.DOI:10.1002/cncr.20734